All High-Throughput Screening (HTS) articles – Page 2
-
NewsSchrödinger partners with Lilly TuneLab on AI drug discovery
Schrödinger has announced a collaboration with Eli Lilly’s TuneLab platform, integrating advanced AI-driven drug discovery workflows into its LiveDesign enterprise informatics system.
-
ArticleWhy tau still lacks treatments and how funders are responding
Tau drives PSP, CBD and other neurodegenerative diseases, yet there are still no disease-modifying treatments. Here, Dr Glenn Harris from the Rainwater Charitable Foundation shares how a coordinated funding effort is supporting basic research to understand tau mechanisms, improve detection and progress therapeutic development.
-
NewsMaternal stress may alter foetal brain development via immune pathways
Stress during pregnancy may disrupt the maternal gut-immune system, altering foetal brain development and revealing sex-specific vulnerabilities linked to neurodevelopmental risk
-
ArticleQuality over quantity: drug discovery automation in 2026
Automation in 2026 is no longer judged by the volume of experiments, but by the reliability of the evidence they produce. As complex biology and tighter budgets collide, industry leaders are pivoting toward automated workflows to secure the data integrity required for confident, early-stage decision-making.
-
NewsNew Type 2 diabetes drugs may improve insulin sensitivity
Scientists have used advanced computer modelling and lab techniques to design potential new diabetes drugs that improve insulin sensitivity.
-
NewsNew study links prenatal DNA screening to better CMV treatment decisions
A new study suggests that a low-cost form of non-invasive prenatal screening could help clinicians identify pregnant women at highest risk of transmitting cytomegalovirus to their babies.
-
NewsNew AI genomics platform targets kidney and cardiorenal disease
Seattle-based biotech company, Variant Bio, have launched Inference, an AI-powered genomics platform designed to accelerate drug discovery and identify genetically supported targets.
-
ArticleFertility beyond IVF: therapeutic advances in reproductive biotech
Procedural advances in IVF are reaching their biological limits. Reproductive biotech is now moving upstream, developing first in class therapeutics that target meiosis, gamete quality and implantation biology as druggable mechanisms in early discovery.
-
ArticleAgentic AI: teaching machines to think like scientists
What happens when AI stops guessing and starts reasoning? Agentic AI is bringing scientific logic into the heart of drug discovery.
-
ArticleThe data fragmentation problem holding drug discovery back
The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of Product at Certara, explains how better infrastructure and AI can help teams work faster and make decisions with more confidence.
-
NewsBrain ‘master switch’ discovery could lead to new neurodegenerative therapies
Scientists have captured, for the first time, dynamic changes in a crucial neuronal ‘master switch’ inside the living brain, potentially informing new future treatments for neurodegenerative diseases.
-
NewsNew research aims to make FDA-approved drugs safer for the brain
Life-saving HIV and cancer drugs can carry serious neurological risks, and new funding will help UMBC researchers discover how these medicines damage the brain – which could help to inform safer treatments.
-
NewsExperimental drug NU-9 reduces toxic amyloid in early Alzheimer’s
A recently developed experimental drug, called NU-9, has shown promise in targeting a toxic form of amyloid beta – halting Alzheimer’s disease before symptoms appear.
-
NewsUltra-stable hydrogel boosts gastrointestinal wound repair
PolyU researchers have developed a new acid-resistant hydrogel inspired by natural gastric mucus that adheres far better than current treatments.
-
NewsHydrogel tech enables global shipping of organoid models
A partnership between Atelerix and Cherry Biotech is enabling the shipping of complex biological models worldwide, using hydrogel preservation technology to eliminate cold-chain logistics.
-
NewsNew AI model links genetic mutations to specific diseases
Scientists have developed a new artificial intelligence tool that can identify harmful genetic mutations and predict the types of diseases they are likely to cause, offering faster diagnosis and new opportunities for drug discovery.
-
WebinarThe truth about AI in drug discovery: what the experts really think
AI in drug discovery is evolving fast. Join the experts behind today’s real progress as they share what works, what doesn’t and what you need to know next.
-
ArticleThe future of obesity drugs starts in preclinical discovery
Progress in preclinical models and biomarker science is improving early-stage obesity drug development. This article outlines the emerging targets and technologies behind this shift.
-
ArticleRNA that lasts longer and lands exactly where it should
RNA therapies are moving past burst-and-fade limits. New advances in circular RNA and targeted delivery could transform how we treat autoimmune disease, infections and beyond.
-
NewsNew Spheromatrix platform speeds up cancer drug research
Researchers at NYU Abu Dhabi have developed a cheap, paper-based platform that allows tumour models to be grown, frozen and stored for future cancer drug testing – called Spheromatrix.